Self-Guided CBT-I Program Improves Insomnia and Associated Mental Health Symptoms
Adults with insomnia symptoms used the CBT-I program over 18 months and reported significant and sustained improvements.
Adults with insomnia symptoms used the CBT-I program over 18 months and reported significant and sustained improvements.
New research reveals that Sleepio reduces anxiety symptoms in individuals with co-existing insomnia and anxiety, while a separate study highlights the treatment's impact on stroke survivors.
Early in my sleep tech career, I figured insomnia was a sleep disorder for the day shift to handle.
How increased awareness of behavioral sleep medicine could be a game-changer for children.
Read MoreThe Coopérative des techniciens ambulanciers de la Montérégie in Canada is offering its members free access to the services of HALEO, a professional virtual sleep clinic.
Read MoreNox Health has closed the acquisition of Somryst, the only FDA-approved prescription digital therapeutic for adults with chronic insomnia, from Pear Therapeutics.
Read MoreThe digital sleep program, which uses CBT-I-based strategies and text-based coaching, showed meaningful improvements in total sleep time for users in a new study.
Read MoreNox Health Group is set to acquire Pear Therapeutics’ Somryst after being selected as the successful bidder at Pear’s bankruptcy auction last week.
Read MoreTeach patients these relaxation exercises as part of their insomnia therapy.
Read MoreThe COVID-19 pandemic offered researchers a rare opportunity to see the effects of a potentially distressing global event on people with sleep reactivity, that is, those who are vulnerable to stress-related sleep disturbances.
Read MoreJennifer L. Martin, PhD, speaks about the challenges faced by people with insomnia disorder in accessing CBT-I and pharmaceuticals, as well as posits solutions.
Read MoreA paper details a health economic analysis of Somryst, including changes in healthcare resource use, associated costs, and insomnia severity.
Read MoreResMed has acquired Leipzig, Germany-based health tech company mementor; the deal was completed on August 1.
Read MoreInsomnia is linked with anxiety and depression, and a clinical trial evaluates the impact of Somryst on these comorbidities.
Read MoreHundreds of thousands of insomnia patients will be offered digital cognitive behavioral therapy via the app Sleepio instead of sleeping pills.
Read MoreTwo abstracts presented at World Sleep 2022 provide data on Somryst’s efficacy at six months and on its use in older adults.
Read MoreBy targeting insomnia and effectively treating it with CBT-I, depression can be effectively prevented by over 50% in community dwelling older adults with insomnia.
Read MoreThe new HCPCS code for Somryst encompasses “Prescription Digital Behavioral Therapy, FDA Cleared, per Course of Treatment.”
Read More